Table 2.
Patients eligible for this study must not meet any of the following criteria at the start of first line treatment.
| 11.Any contraindication to the use of cetuximab, Irinotecan, 5-FU, oxaliplatin, folinic acid, bevacizumab, trifluridine-tipiracil, regorafenib |
| 12. Active uncontrolled infections, active disseminated intravascular coagulation or history of interstitial lung disease |
| 13. Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin cancer or in situ carcinoma of the cervix |
| 14. Pregnancy (exclusion to be ascertained by a beta hCG test |
| 15. Breastfeeding |
| 16. Fertile women (<2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception• |
| 17. Myocardial infarction, unstable angina pectoris, balloon angioplasty (PTCA) with or without stenting within the past 12 months before inclusion in the study, Grade III or IV heart failure (NYHA classification) |
| 18. Cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin |
| 19. Medical or psychological impairments associated with restricted ability to give consent or not allowing conduct of the study |
| 20. Previous chemotherapy for the colorectal cancer with the exception of adjuvant treatment, completed at least 6 months before entering the study |
| 21. Participation in a clinical study or experimental drug treatment within 30 days prior to study inclusion or during participation in the study |
| 22. Known or clinically suspected brain metastases |
| 23. History of acute or subacute intestinal occlusion or chronic inflammatory bowel disease or chronic diarrhoea |
| 24. Severe, non-healing wounds, ulcers or bone fractures |
| 25. Uncontrolled hypertension |
| 26. Marked proteinuria (nephrotic syndrome) |
| 27. Known DPD deficiency (specific screening not required) |
| 28. Known history of alcohol or drug abuse |
| 29. A significant concomitant disease which, in the investigating physician’s opinion, rules out the patient’s participation in the study |
| 30. Absent or restricted legal capacity |